mRNA-1403 norovirus trial misses early-success threshold at Phase 3 interim analysis
Company / institutional announcement · Moderna — SEC-filed company release
Source published: · Event / reporting date: 2026-07-31
Site published: 2026-11-03 · Updated: 2026-11-03
This source is linked automatically. Choose a question to get started.
What changed
Moderna reported that its Phase 3 safety and efficacy trial of the norovirus vaccine candidate mRNA-1403 did not meet the statistical criteria for early success at an interim analysis. The study remains ongoing and blinded, and the company is preparing to enroll another cohort. The announcement does not establish the final efficacy result or show that the entire trial has failed.
Why it may matter
The update highlights uncertainty in a major new vaccine indication and the importance of separating interim stopping boundaries from final efficacy conclusions.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections